SLE is a disease of diverse clinical, serologic and pathologic features. The diversity is likely explained by the inheritance of different combinations of susceptibility genes, possibly in combination with environmental factors. Mice with the lpr and gld phenotype have long been considered a model for SLE. Recently, loss of function mutations in the Fas and Fas ligand genes have been found to be responsible for the phenotype. Over the last funding period, we and others, have gained understanding in how mutations in the Fas apoptotic pathway lead to autoimmunity in mice. In addition to Fas pathway mutations, background genes have a striking effect on clinical expression of autoimmunity in different strains of mice. Humans with the Ipr phenotype were first described in 1967 at the Cornell Medical Center. We have accumulated 10 such families, some with extended pedigrees. The phenotype in individuals with Fas mutations ranges from clinically asymptomatic to full blown SLE. The major goal of this project is to is to identify the additional modifier genes responsible for expression of lupus-like disease in humans. Preliminary studies of families with Fas mutations suggest that a small number of genetic factors with relatively strong effect determine disease expression. Functional analysis of Fas-mediated apoptosis (FMA) in the families of CSS probands have suggested that the additional genetic defect lies in the apoptotic pathway.
Aim 1 A will determine whether family members have abnormalities in the genes or the proteins in the proximal Fas apoptosis pathway (FADD, FLICE and caspases).
Aim I B will determine whether alternative apoptosis pathways such as TNF, DR3, DR4 are impaired in family members.
Aim 2 will test the hypothesis that clinical expression of disease requires the interaction of a heterozygous Fas mutation with a second gene. We will attempt to localize the second gene by linkage analysis and by association studies.
Aim 3 will examine whether the same genetic defects identified in Aims 1 and 2 occur in patients with SLE.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
7R01AR045482-04
Application #
6375149
Study Section
Special Emphasis Panel (ZRG2-ALY (01))
Program Officer
Serrate-Sztein, Susana
Project Start
1998-07-25
Project End
2003-05-31
Budget Start
2001-08-01
Budget End
2002-05-31
Support Year
4
Fiscal Year
2001
Total Cost
$278,192
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Hughes, Grant C; Martin, David; Zhang, Kang et al. (2009) Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice. Arthritis Rheum 60:1775-84
Ogden, Carol Anne; Kowalewski, Robert; Peng, Yufeng et al. (2005) IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38:259-64
Martin, David A; Elkon, Keith B (2004) Mechanisms of apoptosis. Rheum Dis Clin North Am 30:441-54, vii
Baumler, Caroline; Duan, Fei; Onel, Kenan et al. (2003) Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leuk Res 27:841-51
Wurzburger, Robert J; Gupta, Rajarsi; Parnassa, Andrew P et al. (2003) Use of GC clamps in DHPLC mutation scanning. Clin Med Res 1:111-8
Kim, Sun Jun; Gershov, Debra; Ma, Xiaojing et al. (2002) I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 196:655-65
Gershov, D; Kim, S; Brot, N et al. (2000) C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192:1353-64
Shustov, A; Luzina, I; Nguyen, P et al. (2000) Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J Clin Invest 106:R39-47
Vaishnaw, A K; Toubi, E; Ohsako, S et al. (1999) The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 42:1833-42
Vaishnaw, A K; Orlinick, J R; Chu, J L et al. (1999) The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 103:355-63

Showing the most recent 10 out of 12 publications